Baricitinib preserves beta cell function in new-onset type 1 diabetes
1. In this randomized controlled trial, baricitinib, a Janus kinase (JAK) inhibitor, preserved beta cell function and reduced insulin requirement ...
Tag: endocrinology
Surgical remission of Cushing’s disease associated with higher rates of autoimmune disorders
1. In this retrospective cohort study, patients achieving surgical remission of Cushing’s disease (CD) had a higher incidence of autoimmune ...
Testosterone treatment for hypogonadism did not reduce the risk of fractures
1. In this randomized controlled trial, topical testosterone was not superior to placebo in reducing the risk of fractures in ...
Rates of diabetes remission and sustainability from weight loss
1. Diabetes remission was achievable for participants through weight loss by surgery or lifestyle changes. 2. At a median follow-up ...
Monocyte-to-HDL ratio may be an indicator of poor endothelial dysfunction in diabetics
1. This cross-sectional study is the first to identify the monocyte-to-HDL ratio (MHR) as an indicator of poor endothelial dysfunction ...
2 Minute Medicine Rewind January 15, 2024
Short-Stay Units vs Routine Admission From the Emergency Department in Patients With Acute Heart Failure: The SSU-AHF Randomized Clinical Trial ...
Semaglutide improves cardiovascular outcomes in obese patients without diabetes
1. In this randomized-controlled trial, the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide reduced the risk of cardiovascular death, myocardial infarction, ...
Testosterone replacement therapy not associated with prostate cancer risk
1. In a population of men with hypogonadism and PSA concentrations less than 3 ng/mL, patients randomized to receive testosterone ...
Teplizumab effective in maintaining β-cell function in type 1 diabetes
1. In this randomized-controlled trial, two 12-day courses of teplizumab improved C-peptide levels compared to placebo at week 78 in ...
Baricitinib protects β-cell function in new-onset type 1 diabetes
1. In this randomized controlled trial, the Janus kinase (JAK) inhibitor baricitinib was associated with preserved β-cell function compared to ...